Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study
Por:
Pinazo-Durán MD, García-Medina JJ, Sanz-González SM, O'Connor JE, Casaroli-Marano RP, Valero-Velló M, López-Gálvez M, Peris-Martínez C, Zanón-Moreno V and Diaz-Llopis M
Publicada:
1 abr 2021
Ahead of Print:
19 abr 2021
Categoría:
Clinical biochemistry
Resumen:
The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG); n = 36) and healthy controls (control group (CG); n = 36). Each group was randomly assigned to the oral supplementation of one pill/day (+) containing DHA-TG (n = 18) or no-pill condition (-) (n = 17) for three consecutive months. Data from demographics, risk factors, comorbidities, eye complications and therapy were recorded. Blood was collected and processed to determine pro-inflammatory biomarkers by bead-base multiplex assay. Statistical processing with multivariate statistical analysis was performed. The mean age was 50, 12 (10, 31) years. The distribution by gender was 45% males and 55% females. The mean number of uveitis episodes was 5 (2). Higher plasma expression of interleukin (IL)-6 was detected in the UG versus the CG (p = 5 x 10(-5)). Likewise, significantly higher plasma levels were seen for IL-1 beta, IL-2, INF gamma (p = 10(-4)), and TNF alpha (p = 2 x 10(-4)) in the UG versus the CG. Significantly lower values of the above molecules were found in the +DHA-TG than in the -DHA-TG subgroups, after 3 months of follow-up, TNF alpha (p = 10(-7)) and IL-6 (p = 3 x 10(-6)) being those that most significantly changed. Signatures of circulating inflammatory mediators were obtained in the quiescent stage of recurrent NIAU patients. This 3-month follow-up strongly reinforces that a regular oral administration of DHA-TG reduces the inflammatory load and may potentially supply a prophylaxis-adjunctive mediator for patients at risk of uveitis vision loss.
Filiaciones:
:
Ophthalmic Research Unit "Santiago Grisolía", Fundación Investigación Sanitaria y Biomédica (FISABIO), Ave. Gaspar Aguilar 90, 46017 Valencia, Spain
Research Group in Cellular and Molecular Ophthalmo-Biology, Department of Surgery, University of Valencia, Ave. Blasco Ibañez 15, 46010 Valencia, Spain
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
:
Ophthalmic Research Unit "Santiago Grisolía", Fundación Investigación Sanitaria y Biomédica (FISABIO), Ave. Gaspar Aguilar 90, 46017 Valencia, Spain
Research Group in Cellular and Molecular Ophthalmo-Biology, Department of Surgery, University of Valencia, Ave. Blasco Ibañez 15, 46010 Valencia, Spain
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
Department of Ophthalmology, General University Hospital "Morales Meseguer", Ave. Marqués de los Vélez, s/n, 30008 Murcia, Spain
Department of Ophthalmology and Optometry, University of Murcia, Edificio LAIB Planta 5ª, Carretera Buenavista s/n, 30120 El Palmar Murcia, Spain
:
Ophthalmic Research Unit "Santiago Grisolía", Fundación Investigación Sanitaria y Biomédica (FISABIO), Ave. Gaspar Aguilar 90, 46017 Valencia, Spain
Research Group in Cellular and Molecular Ophthalmo-Biology, Department of Surgery, University of Valencia, Ave. Blasco Ibañez 15, 46010 Valencia, Spain
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
O'Connor JE:
Laboratory of Cytomics, Joint Research Unit Principe Felipe Research Center and University of Valencia, 46010 Valencia, Spain
Casaroli-Marano RP:
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
Department of Surgery, School of Medicine and Hospital Clinic de Barcelona, University of Barcelona, 08036 Barcelona, Spain
:
Ophthalmic Research Unit "Santiago Grisolía", Fundación Investigación Sanitaria y Biomédica (FISABIO), Ave. Gaspar Aguilar 90, 46017 Valencia, Spain
Research Group in Cellular and Molecular Ophthalmo-Biology, Department of Surgery, University of Valencia, Ave. Blasco Ibañez 15, 46010 Valencia, Spain
López-Gálvez M:
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
Department of Ophthalmology, University Clinic Hospital of Valladolid, 47003 Valladolid, Spain
:
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
Ophthalmic Medical Center (FOM), Foundation for the Promotion of Health and Biomedical Research of Valencia (FISABIO), 46015 Valencia, Spain
:
Spanish Net of Ophthalmic Research "OFTARED" RD16/0008/0022, of the Institute of Health Carlos III, 28029 Madrid, Spain
Faculty of Health Sciences, Valencian International University, 46002 Valencia, Spain
Diaz-Llopis M:
Research Group in Cellular and Molecular Ophthalmo-Biology, Department of Surgery, University of Valencia, Ave. Blasco Ibañez 15, 46010 Valencia, Spain
Green Published, gold
|